SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 61.97-3.2%Nov 3 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Lance Bredvold
OldAIMGuy
S. maltophilia
To: software salesperson who wrote (52091)9/17/2023 7:11:14 PM
From: software salesperson3 Recommendations   of 52153
 
it turns out that it is not a new concept.

too many diagrams to post link? - - see "An Exciting New Approach to Autoimmune Diseases

ERIC TOPOL

SEP 17, 2023 in his ground truths substack.

here's the summary, as the piece itself is a tad bit complicated:

The approach of leveraging the liver to induce immune tolerance is intriguing and the new published work takes this a step further as a potential treatment in the future. There are still plenty of uncertainties, such as knowing the autoantigens in a particular individual or fully understanding the mechanism of tolerance induction. A tolerogenic vaccine is a huge challenge and orders of magnitude more complex than stimulating the immune system against a particular pathogen. There’s already a graveyard full of failed tolerogenic approaches and it’s certainly possible that glycosylation and the liver pathway could ultimately fail too. Nevertheless, I would deem it as an exciting approach—it it works, it will have a transformative impact on a wide array of self-destructive medical conditions for which we don’t yet have highly effective and safe means for preventing or treating.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News